Patents by Inventor Andrew V. Schally

Andrew V. Schally has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9855312
    Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: January 2, 2018
    Assignees: UNIVERSITY OF MIAMI, THE UNITED STATES OF AMERICA, REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Andrew V. Schally, Joshua M. Hare, Norman L. Block, Samirah A. Gomes, Rosemeire M. Kanashiro-Takeuchi
  • Patent number: 9393271
    Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat diabetes. In one embodiment, a method of promoting survival of grafted cells and/or tissues may involve exposing the cells and/or tissues to an effective amount of at least one agonist of GHRH. In some embodiments, the grafted cells and/or tissues may be pancreatic cells. In some embodiments, the grafted cells may be islet cells co-cultured with non-pancreatic cells. In a further embodiment, a method of treating a patient diagnosed with diabetes involves transplanting and/or grafting the islet cells and/or tissues comprising islet cells into a patient, and administering a therapeutically effective amount of at least one agonist of GHRH to the patient. In some embodiments, the islet cells and/or tissues comprising islet cells may be optionally exposed to GHRH and/or at least one agonist of GHRH prior to transplantation into a patient.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: July 19, 2016
    Assignees: University of Miami, The United States of America, Represented by the Department of Veterans Affairs, Dresden University of Technology
    Inventors: Andrew V. Schally, Norman L. Block, Stefan Bornstein, Barbara Ludwig
  • Publication number: 20160166652
    Abstract: There is provided a novel series of synthetic analogs of hGH-RH(1-29)NH2 (SEQ ID NO: 1) and hGH-RH(1-30)NH2. Of particular interest are those carrying PhAc, N-Me-Aib, Dca, Ac-Ada, Fer, Ac-Amc, Me-NH-Sub, PhAc-Ada, Ac-Ada-D-Phe, Ac-Ada-Phe, Dca-Ada, Dca-Amc, Nac-Ada, Ada-Ada, or CH3—(CH2)10—CO-Ada, at the N-Terminus and ?-Ala, Amc, Apa, Ada, AE2A, AE4P, ?-Lys(?-NH2), Agm, Lys(Oct) or Ahx, at the C-terminus. These analogs inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers, and inhibit the hyperplastic and benign proliferative disorders of various organs, through a direct effect on the cancerous and non-malignant cells. The stronger inhibitory potencies of the new analogs, as compared to previously described ones, result from replacement of various amino acids.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 16, 2016
    Inventors: Andrew V. SCHALLY, Marta ZARANDI, Jozsef L. VARGA, Ren Zhi CAI
  • Patent number: 9260504
    Abstract: There is provided a novel series of synthetic analogs of hGH-RH(1-29)NH2 (SEQ ID NO: 1) and hGH-RH(1-30)NH2. Of particular interest are those carrying PhAc, N-Me-Aib, Dca, Ac-Ada, Fer, Ac-Amc, Me-NH-Sub, PhAc-Ada, Ac-Ada-D-Phe, Ac-Ada-Phe, Dca-Ada, Dca-Amc, Nac-Ada, Ada-Ada, or CH3—(CH2)10—CO-Ada, at the N-Terminus and ?-Ala, Amc, Apa, Ada, AE2A, AE4P, ?-Lys(?-NH2), Agm, Lys(Oct) or Ahx, at the C-terminus. These analogs inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers, and inhibit the hyperplastic and benign proliferative disorders of various organs, through a direct effect on the cancerous and non-malignant cells. The stronger inhibitory potencies of the new analogs, as compared to previously described ones, result from replacement of various amino acids.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: February 16, 2016
    Assignees: University of Miami, The United States of America, Represented by the Department of Veterans Affairs
    Inventors: Andrew V. Schally, Marta Zarandi, Jozsef L. Varga, Ren Zhi Cai
  • Publication number: 20150274798
    Abstract: There are provided a novel series of peptide analogs of hGH-RH(1-29)NH2 and hGH-RH(1-30)NH2 which show high activities in stimulating the release of pituitary GH in animals. They retain their physiological activity in solution for extended periods of time and resist enzymic degradation in the body. These novel and useful properties appear to be due to novel substitution patterns ant at the 1, 15, 27 and 29 positions on the peptide.
    Type: Application
    Filed: June 11, 2015
    Publication date: October 1, 2015
    Inventors: Andrew V. SCHALLY, Ren Zhi CAI, Marta ZARANDI
  • Patent number: 9079974
    Abstract: There are provided a novel series of peptide analogs of hGH-RH(1-29)NH2 and hGH-RH(1-30)NH2 which show high activities in stimulating the release of pituitary GH in animals. They retain their physiological activity in solution for extended periods of time and resist enzymic degradation in the body. These novel and useful properties appear to be due to novel substitution patterns ant at the 1, 15, 27 and 29 positions on the peptide.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: July 14, 2015
    Assignees: The University of Miami, The United States of America, represented by the Department of Veterans Affairs
    Inventors: Andrew V Schally, Ren Zhi Cai, Marta Zarandi
  • Publication number: 20150174207
    Abstract: Embodiments of the present disclosure are directed to methods to treat a subject having cancer. In one embodiment, a method of treating a subject with cancer may comprise administering a therapeutically effective amount of at least one GHRH agonist peptide in combination with at least one anticancer agent. In another embodiment, a method of killing cancer cells may comprise contacting the cancer cells with a composition comprising at least one GHRH agonist peptide and at least one anticancer agent. In some embodiments, the method may be in vitro or in vivo. In an additional embodiment, a method of killing cancer stem cells may comprise contacting the cancer stem cells with a composition comprising at least one GHRH agonist peptide and at least one anticancer agent.
    Type: Application
    Filed: December 24, 2014
    Publication date: June 25, 2015
    Inventors: Andrew V. SCHALLY, Miklos JASBERENYI
  • Publication number: 20150166617
    Abstract: Disclosed herein are compositions of GHRH peptide antagonists, and methods to treat Alzheimer's disease and other neurodegenerative disorders. Such compounds are useful for therapeutics, for protecting neuronal cells from cell-death and for promoting neuronal cell viability.
    Type: Application
    Filed: June 27, 2013
    Publication date: June 18, 2015
    Inventors: Andrew V. Schally, Miklos Jasberenyi, Norman L. Block
  • Patent number: 8980249
    Abstract: Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: March 17, 2015
    Assignees: University of Miami, Dresden University of Technology
    Inventors: Andrew V. Schally, Barbara Ludwig, Stefan Bornstein, Norman L. Block
  • Publication number: 20140206836
    Abstract: There is provided a novel series of synthetic analogs of hGH-RH(1-29)NH2 (SEQ ID NO: 1) and hGH-RH(1-30)NH2. Of particular interest are those carrying PhAc, N-Me-Aib, Dca, Ac-Ada, Fer, Ac-Amc, Me-NH-Sub, PhAc-Ada, Ac-Ada-D-Phe, Ac-Ada-Phe, Dca-Ada, Dca-Amc, Nac-Ada, Ada-Ada, or CH3—(CH2)10—CO-Ada, at the N-Terminus and ?-Ala, Amc, Apa, Ada, AE2A, AE4P, ?-Lys(?-NH2), Agm, Lys(Oct) or Ahx, at the C-terminus. These analogs inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers, and inhibit the hyperplastic and benign proliferative disorders of various organs, through a direct effect on the cancerous and non-malignant cells. The stronger inhibitory potencies of the new analogs, as compared to previously described ones, result from replacement of various amino acids.
    Type: Application
    Filed: February 19, 2014
    Publication date: July 24, 2014
    Applicants: U.S.A., represented by the Department of Veterans Affairs, University of Miami
    Inventors: Andrew V. SCHALLY, Marta ZARANDI, Jozsef L. VARGA, Ren Zhi CAI
  • Publication number: 20140193378
    Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat diabetes. In one embodiment, a method of promoting survival of grafted cells and/or tissues may involve exposing the cells and/or tissues to an effective amount of at least one agonist of GHRH. In some embodiments, the grafted cells and/or tissues may be pancreatic cells. In some embodiments, the grafted cells may be islet cells co-cultured with non-pancreatic cells. In a further embodiment, a method of treating a patient diagnosed with diabetes involves transplanting and/or grafting the islet cells and/or tissues comprising islet cells into a patient, and administering a therapeutically effective amount of at least one agonist of GHRH to the patient. In some embodiments, the islet cells and/or tissues comprising islet cells may be optionally exposed to GHRH and/or at least one agonist of GHRH prior to transplantation into a patient.
    Type: Application
    Filed: December 23, 2013
    Publication date: July 10, 2014
    Applicants: UNIVERSITY OF MIAMI, DRESDEN UNIVERSITY OF TECHNOLOGY, U.S.A., REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Andrew V. SCHALLY, Norman L. BLOCK, Stefan BORNSTEIN, Barbara LUDWIG
  • Publication number: 20140179604
    Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide.
    Type: Application
    Filed: December 23, 2013
    Publication date: June 26, 2014
    Applicants: U.S.A., REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, UNIVERSITY OF MIAMI
    Inventors: Andrew V. SCHALLY, Joshua M. HARE, Norman L. BLOCK, Samirah A. GOMES, Rosemeire M. KANASHIRO-TAKEUCHI
  • Patent number: 8691942
    Abstract: There is provided a novel series of synthetic analogs of hGH-RH(1-29)NH2 (SEQ ID NO: 1) and hGH-RH(1-30)NH2. Of particular interest are those carrying PhAc, N-Me-Aib, Dca, Ac-Ada, Fer, Ac-Amc, Me-NH-Sub, PhAc-Ada, Ac-Ada-D-Phe, Ac-Ada-Phe, Dca-Ada, Dca-Amc, Nac-Ada, Ada-Ada, or CH3—(CH2)10—CO-Ada, at the N-Terminus and ?-Ala, Amc, Apa, Ada, AE2A, AE4P, ?-Lys(?-NH2), Agm, Lys(Oct) or Ahx, at the C-terminus. These analogs inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers, and inhibit the hyperplastic and benign proliferative disorders of various organs, through a direct effect on the cancerous and non-malignant cells. The stronger inhibitory potencies of the new analogs, as compared to previously described ones, result from replacement of various amino acids.
    Type: Grant
    Filed: September 25, 2010
    Date of Patent: April 8, 2014
    Assignees: University of Miami, U.S.A. Represented by the Dept. of Veterans Affairs
    Inventors: Andrew V. Schally, Marta Zarandi, Jozsef L. Varga, Ren Zhi Cai
  • Publication number: 20140057847
    Abstract: Disclosed herein are methods demonstrating that growth-hormone releasing hormone (GHRH) directly activates cellular reparative mechanisms within the injured heart, in a GH/IGF-I independent fashion. Following experimental myocardial infarction (MI), rats were randomly assigned to receive, during a 4 week period, either placebo (n=14), rat recombinant GH (rrGH, n=8) or JI-38 (n=8; 50 ?g/Kg/day), a potent GHRH-agonist. JI-38 did not elevate serum levels of GH or IGF-I, but markedly attenuated the degree of cardiac functional decline and remodeling after injury. In contrast, GH administration markedly elevated body weight, heart weight, circulating GH and IGF-I, but did not offset the decline in cardiac structure and function. Whereas, both JI-38 and GH augmented levels of cardiac precursor cell proliferation, only JI-38 increased anti-apoptotic gene expression. Collectively, these findings demonstrate that within the heart, GHRH-agonists can activate cardiac repair following MI.
    Type: Application
    Filed: July 22, 2013
    Publication date: February 27, 2014
    Applicants: United States of America, Represented by The Department of Veterans Affairs, University of Miami
    Inventors: Andrew V. SCHALLY, Norman L. Block, Joshua M. Hare, Rosemeire Miyuki Kanashiro-Takeuchi
  • Publication number: 20140058068
    Abstract: There are provided a novel series of peptide analogs of hGH-RH(1-29)NH2 and hGH-RH(1-30)NH2 which show high activities in stimulating the release of pituitary GH in animals. They retain their physiological activity in solution for extended periods of time and resist enzymic degradation in the body. These novel and useful properties appear to be due to novel substitution patterns ant at the 1, 15, 27 and 29 positions on the peptide.
    Type: Application
    Filed: December 21, 2011
    Publication date: February 27, 2014
    Inventors: Andrew V. Schally, Ren Zhi Cai, Marta Zarandi
  • Publication number: 20130261055
    Abstract: There is provided a novel series of synthetic analogs of hGH-RH(1-29)NH2 (SEQ ID NO: 96) and hGH-RH(1-30)NH2. Of particular interest are those carrying PhAc, N-Me-Aib, Dca, Ac-Ada, Fer, Ac-Amc, Me-NH-Sub, PhAc-Ada, Ac-Ada-D-Phe, Ac-Ada-Phe, Dca-Ada, Dca-Amc, Nac-Ada, Ada-Ada, or CH3—(CH2)10—CO-Ada, at the N-Terminus and ?-Ala, Amc, Apa, Ada, AE2A, AE4P, ?-Lys(?-NH2), Agm, Lys(Oct) or Ahx, at the C-terminus. These analogs inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers, and inhibit the hyperplastic and benign proliferative disorders of various organs, through a direct effect on the cancerous and non-malignant cells. The stronger inhibitory potencies of the new analogs, as compared to previously described ones, result from replacement of various amino acids.
    Type: Application
    Filed: September 25, 2010
    Publication date: October 3, 2013
    Inventors: Andrew V. Schally, Marta Zarandi, Jozsef L. Varga, Ren Zhi Cai
  • Publication number: 20130261058
    Abstract: Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists.
    Type: Application
    Filed: September 16, 2011
    Publication date: October 3, 2013
    Applicants: University of Miami, U.S. Department of Veterans Affairs, National and Kapodistrian University of Athens
    Inventors: Andrew V. Schally, Hippokratis Kiaris, Norman L. Block
  • Patent number: 8507433
    Abstract: Whether the growth hormone (GH)/Insulin-like growth factor 1(IGF-I) axis exerts cardioprotective effects remains controversial; and the underlying mechanism(s) for such actions are unclear. Here we tested the hypothesis that growth-hormone releasing hormone (GHRH) directly activates cellular reparative mechanisms within the injured heart, in a GH/IGF-I independent fashion. Following experimental myocardial infarction (MI), rats were randomly assigned to receive, during a 4 week period, either placebo (n=14), rat recombinant GH (rrGH, n=8) or JI-38 (n=8; 50 ?g/Kg/day), a potent GHRH-agonist. JI-38 did not elevate serum levels of GH or IGF-I, but markedly attenuated the degree of cardiac functional decline and remodeling after injury. In contrast, GH administration markedly elevated body weight, heart weight, circulating GH and IGF-I, but did not offset the decline in cardiac structure and function.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: August 13, 2013
    Assignees: University of Miami, The United States of America, represented by the Deptartment of Veterans Affairs
    Inventors: Andrew V. Schally, Norman L Block, Joshua Hare, Rosemeire Miyuki Kanashiro Takeuchi
  • Publication number: 20130195807
    Abstract: Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists.
    Type: Application
    Filed: June 3, 2011
    Publication date: August 1, 2013
    Inventors: Andrew V. Schally, Barbara Ludwig, Stefan Bornstein, Norman L. Block
  • Publication number: 20100152114
    Abstract: There are provided means for suppressing the Reactive Oxidant Species (ROS) of certain cells by the administration of GHRH antagonists. The therapeutic applications of the anti-oxidative action of GH-RH antagonists relate to the redox status of certain cells, including but not limited to cancer cells, reducing the metabolism of reactive oxygen and nitrogen species. This antioxidant activity of GHRH antagonists is employable in the treatment of diseases in which their pathogenesis is related to increased cellular level of oxidative stress.
    Type: Application
    Filed: November 29, 2009
    Publication date: June 17, 2010
    Inventors: Andrew V. Schally, Nektarios Barabutis